Qualitative detection of human IgM antibodies against SARS-CoV-2 in serum or plasma
Sars-CoV-2 - or formerly 2019-nCoV, "2019 novel corona virus" - is the name of a virus identified at the turn of the year 2019/2020 in the Chinese province of Wuhan. The virus causes COVID-19 (corona virus disease 2019), a respiratory disease. The disease spreads via droplet infection and has been detected in the secretions of the nose and throat, sputum, tear fluid and stool. (Detection of the virus: via PCR)
The incubation period can be up to 14 days. Infection of other people is possible already during the incubation period - even if persons are free of symptoms. Likewise, there is an explicit risk of spreading in the case of a subjectively asymptomatic course. The symptoms may be fever, dry cough and muscle pain, sometimes also general fatigue and diarrhoea. In severe cases, pneumonia may develop or intensive medical care may be required.
Since the courses of the disease are very different and the virus is very infectious, it is not sufficient to isolate only clinically conspicuous individuals for quarantine measures. Here, or for epidemiological studies, it is useful to test not only for the presence of the virus, but also for IgM or IgG antibodies against SARS-CoV-2 in the course of a suspected COVID-19 disease.
IgM antibodies are the body's first immune response and are produced in response to the viral antigen. IgM antibodies are primarily present during the early course of the disease and serve as evidence of infection with SARS-CoV-2 and thus COVID-19 infectious disease.
The ELISA is specific for human IgM antibodies directed against SARS-CoV-2 antigen and contains a positive and negative control.
The test uses 2 x 10 µl human plasma or serum samples for duplicate determination in the ELISA.
Coronavirus COVID-19 IgM ELISA Kit KKT1033
In vitro diagnostic agent for the determination of IgG antibodies against SARS-CoV-2 in plasma and serum.